NasdaqCM - Delayed Quote USD

Alzamend Neuro, Inc. (ALZN)

0.7195 -0.0065 (-0.90%)
At close: April 26 at 4:00 PM EDT
0.7500 +0.03 (+4.24%)
After hours: April 26 at 6:29 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ALZN

Recent News: ALZN

View More
Insiders Are Buying These 11 Penny Stocks

Insiders Are Buying These 11 Penny Stocks
Insider Monkey 25 days ago
EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year

EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year
Benzinga 4 months ago
Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients

Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
Business Wire 4 months ago
Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients

Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients
Business Wire 5 months ago
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
Business Wire 5 months ago
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
Business Wire 5 months ago
Alzamend Neuro Announces Reverse Stock Split

Alzamend Neuro Announces Reverse Stock Split
Business Wire 5 months ago
EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder

EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder
Benzinga 6 months ago
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001
Business Wire 6 months ago
EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder

EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder
Benzinga 6 months ago
Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
Business Wire 6 months ago
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement

Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
Business Wire 7 months ago
View More

Related Tickers

BCDA BioCardia, Inc.
0.3766
+2.95%
 
AZTR Azitra, Inc.
0.2185
-0.73%
 
ENSC Ensysce Biosciences, Inc.
0.5842
+1.69%
 
SMMT Summit Therapeutics Inc.
3.8600
+8.73%
 
FNCH Finch Therapeutics Group, Inc.
2.3200
+3.11%
 
ATHE Alterity Therapeutics Limited
2.5100
+9.61%
 
KA Kineta, Inc.
0.6100
-2.37%
 
LIPO Lipella Pharmaceuticals Inc.
0.7110
+0.98%
 
KZIA Kazia Therapeutics Limited
0.3700
+1.43%
 
FBRX Forte Biosciences, Inc.
0.7163
-0.07%